EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Finch Therapeutics Group's Enterprise Value is $29.80 Mil.
Finch Therapeutics Group's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was $-18.06 Mil. Therefore, Finch Therapeutics Group's EV-to-FCF for today is -1.65.
The historical rank and industry rank for Finch Therapeutics Group's EV-to-FCF or its related term are showing as below:
FNCHQ'
s EV-to-FCF Range Over the Past 10 Years
Min: -1.65 Med: 0 Max: 0
Current: -1.65
FNCHQ's EV-to-FCF is not ranked
in the Biotechnology industry.
Industry Median: 14.65
vs FNCHQ: -1.65
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Finch Therapeutics Group (OTCPK:FNCHQ) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Finch Therapeutics Group's PE Ratio (TTM) for today is calculated as:
Finch Therapeutics Group's share price for today is $10.49.
Finch Therapeutics Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.820.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Finch Therapeutics Group EV-to-FCF Related Terms
Finch Therapeutics Group EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Finch Therapeutics Group's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Finch Therapeutics Group EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Finch Therapeutics Group's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Finch Therapeutics Group's EV-to-FCF falls into.
Finch Therapeutics Group's current Enterprise Value is $29.80 Mil.
Finch Therapeutics Group's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-18.06 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Finch Therapeutics Group (FNCHQ) has a EV-to-FCF of -1.65 as of Jun. 26, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Finch Therapeutics Group and its competitors.
Is Finch Therapeutics Group's EV-to-FCF too high?
Finch Therapeutics Group's current EV-to-FCF is -1.65. Overall, Finch Therapeutics Group has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Finch Therapeutics Group's EV-to-FCF compare to CRIS and LSB?
Finch Therapeutics Group's EV-to-FCF of -1.65 can be compared against companies in the Biotechnology industry. The industry median EV-to-FCF is 14.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.65, based on 333 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Finch Therapeutics Group and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Finch Therapeutics Group's current EV-to-FCF is -1.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Finch Therapeutics Group stock overvalued right now?
Finch Therapeutics Group (FNCHQ) has a current EV-to-FCF of -1.65. The current EV-to-FCF is -1.65. Finch Therapeutics Group's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Finch Therapeutics Group (FNCHQ), the current EV-to-FCF is -1.65 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Finch Therapeutics Group Inc is a microbiome technology company with a portfolio of intellectual property and microbiome assets. Finch has a robust intellectual property estate reflecting the company's pioneering role in the microbiome therapeutics field, including more than 70 issued U.S. and foreign patents with critical relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. The company's assets include CP101, an investigational, orally administered microbiome candidate with positive clinical data from a Phase 2 randomized, placebo-controlled trial and a Phase 2 open-label trial in recurrent C. difficile infection (CDI).
12GF Score
Get the complete analysis for FNCHQ
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FNCHQ has been successfully added to your 
